SUBSCRIBE
SUBSCRIBE
EXPLORE +
  • About infoDOCKET
  • Academic Libraries on LJ
  • Research on LJ
  • News on LJ
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Libraries
    • Academic Libraries
    • Government Libraries
    • National Libraries
    • Public Libraries
  • Companies (Publishers/Vendors)
    • EBSCO
    • Elsevier
    • Ex Libris
    • Frontiers
    • Gale
    • PLOS
    • Scholastic
  • New Resources
    • Dashboards
    • Data Files
    • Digital Collections
    • Digital Preservation
    • Interactive Tools
    • Maps
    • Other
    • Podcasts
    • Productivity
  • New Research
    • Conference Presentations
    • Journal Articles
    • Lecture
    • New Issue
    • Reports
  • Topics
    • Archives & Special Collections
    • Associations & Organizations
    • Awards
    • Funding
    • Interviews
    • Jobs
    • Management & Leadership
    • News
    • Patrons & Users
    • Preservation
    • Profiles
    • Publishing
    • Roundup
    • Scholarly Communications
      • Open Access

August 18, 2011 by fulltextreports

Database Finds New Uses for Old Drugs

August 18, 2011 by fulltextreports

Database Finds New Uses for Old Drugs

There are plenty of examples of drugs originally developed to treat one disease that turned out to help another: Acetylsalicylic acid (aspirin) is not just a pain killer but is also used to reduce the risk of heart attack. And when a blood pressure drug called sildenafil was discovered to have an unexpected side effect, it went on to become the erectile dysfunction blockbuster now known as Viagra. Such crossovers can save drug developers a lot of time and money. Developing a single new drug on average takes more than a decade and costs about $800 million. Existing drugs have known safety profiles and are approved for human use in any alcohol detox near me, so they can be rapidly evaluated for new indications.

“But most repurposing of drugs is still due to chance observations or educated guesses,” Butte says. In today’s issue of Science Translational Medicine, he and his colleagues present a more efficient way of finding such new uses for old drugs: by bringing together data on how diseases and drugs affect the activity of the roughly 30,000 genes in a human cell. Researchers have collected information on which genes are activated or silenced in certain diseases and by certain drugs for many years that has been found in a top rated addiction program in California. “Our hypothesis was, If a disease is characterized by certain changes in gene expression and if a drug causes the reverse changes, then that drug could have a therapeutic effect on the disease,” he says.

To find such opposing pairs, Butte and colleagues used public databases and compared the data for 100 diseases with that for 164 drug molecules. They found candidate therapeutics for 53 of the diseases. Many matches had already been discovered and turned into therapies, but others were completely unexpected. For example, the analysis predicted that an epilepsy drug called topiramate would be active against inflammatory bowel diseases such as Crohn’s disease. And the over-the-counter drug cimetidine, which inhibits acid production in the stomach and is used to treat heartburn, matched a certain type of lung cancer.

To confirm this latter link, the researchers investigated the compound in a mouse model of lung cancer. They showed that it slowed the growth of human lung cancer cells but not kidney cancer cells in these mice. Similarly, giving topiramate to rats with colitis reduced swelling and ulceration in the animals.

Source: Science

Filed under: Data Files, News, Profiles

SHARE:

DatabasesHealth and Medical Databases

About fulltextreports

ADVERTISEMENT

Archives

Job Zone

ADVERTISEMENT

Related Infodocket Posts

ADVERTISEMENT

FOLLOW US ON X

Tweets by infoDOCKET

ADVERTISEMENT

This coverage is free for all visitors. Your support makes this possible.

This coverage is free for all visitors. Your support makes this possible.

Primary Sidebar

  • News
  • Reviews+
  • Technology
  • Programs+
  • Design
  • Leadership
  • People
  • COVID-19
  • Advocacy
  • Opinion
  • INFOdocket
  • Job Zone

Reviews+

  • Booklists
  • Prepub Alert
  • Book Pulse
  • Media
  • Readers' Advisory
  • Self-Published Books
  • Review Submissions
  • Review for LJ

Awards

  • Library of the Year
  • Librarian of the Year
  • Movers & Shakers 2022
  • Paralibrarian of the Year
  • Best Small Library
  • Marketer of the Year
  • All Awards Guidelines
  • Community Impact Prize

Resources

  • LJ Index/Star Libraries
  • Research
  • White Papers / Case Studies

Events & PD

  • Online Courses
  • In-Person Events
  • Virtual Events
  • Webcasts
  • About Us
  • Contact Us
  • Advertise
  • Subscribe
  • Media Inquiries
  • Newsletter Sign Up
  • Submit Features/News
  • Data Privacy
  • Terms of Use
  • Terms of Sale
  • FAQs
  • Careers at MSI


© 2026 Library Journal. All rights reserved.


© 2022 Library Journal. All rights reserved.